Web Analytics Made Easy - StatCounter

Research Articles

Russo’s Grand Unified Theory

By | News, Research, Research Articles

Ethan Russo forwards his paper, Grand Unified Theory (GUT): The Endcannabinoid System, Cannabis and the Microbiome just published in Frontiers of Integrative Neuroscience. Russo notes:

“This article addresses five critical areas of clinical neurology practice wherein conventional medicine has fallen short: epilepsy, brain tumors, Parkinson disease, Alzheimer disease, traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE), and how cannabis-based treatment and nutritional approaches with prebiotics and probiotics may provide more effective treatment.”

The paper, which will be the basis of Russo’s talk at the CannMed conference in LA October 23, begins with this overview:

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE). Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB1 and CB2(tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPARγ; THCA), 5-HT1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics. The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment. Read More

Research Pioneer: Ethan Russo MD

By | Research, Research Articles

ethan-russo2Ethan Russo, MD, is a board-certified neurologist and psychopharmacology researcher. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.

Read More

Out Of The Shadows

By | Research Articles

Out Of The Shadows

Published in the Spring 2014 issue of Sonoma Medicine, this article asks physicians to: “For just a few minutes, try to set aside your ideas and opinions about cannabis. Forget about the pot-heads, the pot-docs, the stoners, the jokes, the dispensaries, the bud tenders and the feds.”

Read More

The Effect Of Medical Marijuana Laws On Crime

By | Crime, Research Articles

The Effect Of Medical Marijuana Laws On Crime | Medical Marijuana and Crime

Relying on U.S. state panel data, researchers in Texas analyzed the association between state medical marijuana legalization (MML) and state crime rates for all Part I offenses collected by the FBI. The results did not indicate a crime exacerbating effect of MML on any of the Part I offenses. Alternatively, state medical marijuana legalization may be correlated with a reduction in homicide and assault rates, net of other covariates. Read More

THC & Exercise Performance

By | Endocannabinoid System, Research Articles, THC

THC And Exercise Performance | THC Research

In a 2013 issue of the journal Nutrition & Metabolism, four drugs (ethanol, caffeine, nicotine & THC) were evaluated for their effect on exercise metabolism. Overall, it appears that cannabis does not have ergogenic potential in sports activities and thus, its inclusion on the banned list is likely a function of its illicitness. Read More

Cannabinoid Receptor Pharmacology

By | CBD, Endocannabinoid System, Research Articles, THC, THCV

Cannabinoid Receptor Pharmacology | Cannabinoid Receptor Agonists

Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review published in 2008 in the Journal of British Pharmacology focuses on the manner with which three of these compounds, (_)-trans-D9-tetrahydrocannabinol (D9-THC), (_)-cannabidiol (CBD) and (_)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid receptors CB1 and CB2. Read More

Cannabidiol As A Potential Treatment For Psychosis

By | Research Articles

CBD and Psychosis | Cannabis for Psychosis

Published in the November 2013 issue of European Neuropsychopharmacology, this review of the literature looked at CBD as a potential treatment for psychosis. Human studies found that THC and CBD have very distinct effects on several psychological and physiological parameters associated with psychosis. Evidence from several study domains suggests that CBD has some potential as an antipsychotic treatment. Read More

THC and COX2 Mediation

By | Research Articles, THC

THC and COX2 Mediation | Ibuprofen THC | NSAIDS THC

This study, from Louisiana State University and published in the journal Cell in November, 2013 showed that unwanted side effects of THC-Rich cannabis could be eliminated or reduced while retaining its beneficial effects by administering a COX-2 inhibitor or NSAID along with THC. Read More